Virtual Library
Start Your Search
J. Tang
Author of
-
+
P3.02c - Poster Session with Presenters Present (ID 472)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-016 - Efficacy of Bevacizumab Combined with Chemotherapy in Lung Adenocarcinoma-Induced Malignant Pleural Effusion (ID 5276)
14:30 - 14:30 | Author(s): J. Tang
- Abstract
Background:
Malignant pleural effusion(MPE) is a common complication in advanced lung cancer, with multiple symptoms and poor prognosis. Vascular endothelial growth factor (VEGF) was considered important in the formation of MPE. We aimed to investigate the efficacy of bevacizumab plus chemotherapy in the treatment of MPE due to lung adenocarcinoma.
Methods:
Data of 18 lung adenocarcinoma patients with MPE were analyzed retrospectively. All the patients were treated with bevacizumab plus chemotherapy with 3 weeks in one cycle, up to 6 cycles. Those who exhibited response or stable disease received maintenance therapy of bevacizumab till disease progression. The primary outcomes were control rate of MPE, progression free survival(PFS), pleural progression-free survival (PPFS) and changes in the lung volumn and thoracic cage. Evaluation by CT scan was done every 6 weeks.
Results:
All the 18 cases were evaluable for response. Median age was 59 years(29 years-74 years). There were 14 chemotherapy-naïve patients and 4 relapsing patients. Median numbers of cycles were 7(1-42) for bevacizumab and 5(2-6) for chemotherapy. Median duration of follow-up was 596 days(76-1752 days). Control rate of MPE at 6 weeks, 12 weeks, 24 weeks, 48 weeks, 96weeks were 94.4%, 88.9%, 88.2%, 66.7%, 40.0% respectively. The response rate of MPE to combine treatment reached 77.8%. Median PPFS was significantly longer than PFS(734days vs 254 days, P=0.039). The overall survival was 773 days. 16(88.9%) patients experienced lung reexpansion after treatment. Only one(5.6%) patient suffered from thoracic cage diminishment in treatment and follow-up period. Side effects of bevacizumab-based regimens included myelosuppression, digestive symptoms, bleeding, hypertension, proteinuria, etc. Most of them were grade 1-2.Observation Items Outcomes Response in Measurable Lesions CR PR SD PD RR n(%) 0(0) 8(44.4) 9(50.0) 1(5.6) 8(44.4) Response in MPE CR PR NC PD RR n(%) 7(38.9) 7(38.9) 3(16.7) 1(5.6) 14(77.8) Control Rate of MPE 6weeks 12weeks 24weeks 48weeks 96weeks n(%) 17(94.4) 16(88.9) 15(88.2) 10(66.7) 6(40.0) MPE Conditions at the Time of Measurable Lesions PD CR PR NC PD n(%) 5(35.7) 6(42.9) 0(0) 3(21.4) Changes in the Lung Volume and Thoracic Cage Lung Reexpansion ≥ 70% Thoracic Cage Diminishment n(%) 16(88.9) 1(5.6) Survival PFS PPFS OS Median(day) 254 734 773
Conclusion:
Bevacizumab combined with chemotherapy demonstrated efficacious, persistent and safety in controlling MPE caused by lung adenocarcinoma. It was suggested that lung adenocarcinoma patients complicated with MPE are more likely to get benefit from bevacizumab-based chemotherapy.
